Abionyx Pharma SA
PAR:ABNX

Watchlist Manager
Abionyx Pharma SA Logo
Abionyx Pharma SA
PAR:ABNX
Watchlist
Price: 3.73 EUR -3.62%
Market Cap: 130.3m EUR

Abionyx Pharma SA
Investor Relations

ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Sir Cyrille Tupin CPA
CEO, GM & Director
No Bio Available
Prof. Christian Chavy MBA
Independent Director
No Bio Available
Mr. Emmanuel De Fougeroux
Administrative & Financial Director
No Bio Available
Ms. Constance Keyserling Peyrottes M.S.
Vice President of Clinical, Regulatory Development & Operations
No Bio Available
Dr. Robert Andrew Donald Scott M.D.
Chief Medical Officer and Head of R&D
No Bio Available
Mr. Laurent Guerci
Chief Digital & Innovation Officer
No Bio Available

Contacts

Address
OCCITANIE
Balma
Bat. D 33-43 Avenue Georges Pompidou
Contacts
+33562249706.0
www.abionyx.com